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Objectives We sought to determine whether the differences in outcomes present between everolimus-eluting stents (EES)
and paclitaxel-eluting stents (PES) in the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary
Stent System) IV trial at 1 year were sustained with longer-term follow-up.
Background In the SPIRIT IV trial, patients undergoing percutaneous coronary intervention who were randomized to EES com-
pared with PES experienced lower 1-year rates of target lesion failure (cardiac death, target vessel myocardial
infarction [MI], or ischemia-driven target lesion revascularization [TLR]), with significant reductions in the individ-
ual rates of MI, TLR, and stent thrombosis.
Methods We prospectively randomized 3,687 patients with up to 3 noncomplex previously untreated native coronary ar-
tery lesions to EES versus PES at 66 U.S. sites. Follow-up through 2 years is complete in 3,578 patents (97.0%).
Results Treatment with EES compared with PES reduced the 2-year rates of TLF (6.9% vs. 9.9%, p  0.003), all MI
(2.5% vs. 3.9%, p  0.02), Q-wave MI (0.1% vs. 0.8%, p  0.002), stent thrombosis (0.4% vs. 1.2%, p  0.008),
and ischemia-driven TLR (4.5% vs. 6.9%, p  0.004), with nonsignificantly different rates of all-cause and car-
diac mortality. Between 1 year and 2 years, there were no significant differences in adverse event rates between
the 2 stent types.
Conclusions In the large-scale, prospective, multicenter, randomized SPIRIT IV trial, the benefits of EES compared with those
of PES present at 1 year were sustained at 2 years. (Clinical Evaluation of the XIENCE V Everolimus Eluting Coro-
nary Stent System; NCT01016041) (J Am Coll Cardiol 2011;58:19–25) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.022Compared with bare-metal stents, drug-eluting stents
(DES) delivering either paclitaxel or sirolimus to the site
of arterial injury during percutaneous coronary interven-
tion (PCI) safely reduce clinical restenosis, resulting in
improved event-free survival (1,2). Next-generation DES
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2-Year Outcomes of the SPIRIT IV Trial June 28, 2011:19–25ity trials designed for regulatory
approval. Given the low frequency
of adverse events with contempo-
rary DES, large-scale trials are re-
quired to determine whether sig-
nificant differences exist between
devices, which are clinically rele-
vant given their annual use in more
than 2 million patients worldwide.
In the SPIRIT (Clinical Eval-
uation of the XIENCE V Ever-
olimus Eluting Coronary Stent
System) IV trial, 3,687 patients
undergoing PCI were randomized
to everolimus-eluting stents (EES)
versus paclitaxel-eluting stents (PES), representing the larg-
est reported comparison of 2 DES to date (3). The 1-year
primary endpoint of target lesion failure (TLF) (cardiac
death, target vessel myocardial infarction [MI], or ischemia-
driven target lesion revascularization [TLR]) was reduced
from 6.7% with PES to 4.0% with EES (p  0.0009), with
significant reductions in the individual rates of MI, TLR,
and stent thrombosis. Whether these benefits are robust
over time has not been reported. In this regard, serial
angiographic follow-up in a modest number of patients
from the SPIRIT II trial suggested that there may be greater
incremental late loss with EES than PES between 6 months
and 2 years, which could theoretically narrow the clinical
differences between these 2 devices (4). We therefore
Baseline Clinical and Angiographic CharacteristTable 1 Baseline Clinical and Angiographic
(n  2,
and 3,1
Demographic features
Age, yrs 63.
Male 1,665/
Hypertension 1,899/
Hypercholesterolemia 1,834/
Diabetes mellitus 786/
Insulin requiring 209/
Current smoker 527/
Prior myocardial infarction 504/
Unstable angina 669/
No. of target lesions/patient 1.
Target lesion characteristics
Reference vessel diameter, mm 2.7
Minimal luminal diameter, mm 0.7
Diameter stenosis, % 72.
Lesion length, mm 14.
Procedural variables
No. of stents/patient 1.4
No. of stents/lesion 1.1
Maximum stent diameter/lesion, mm 3.0
Total stent length/lesion, mm 22.
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
TLF  target lesion failure
TLR  target lesion
revascularizationData are presented as mean  SD or n (%).
EES  everolimus-eluting stent(s); PES  paclitaxel-eluting stent(s).describe the 2-year clinical outcomes from the large-scale
SPIRIT IV trial.
Methods
Patients and protocol. As previously described (3,5),
SPIRIT IV was a prospective, multicenter, randomized,
single-blind, active-controlled clinical trial in which 3,687
patients18 years undergoing PCI were randomized 2:1 to
EES (XIENCE V, Abbott Vascular, Santa Clara, Califor-
nia) or PES (TAXUS Express-2, Boston Scientific, Natick,
Massachusetts). Patients undergoing PCI of up to 3 previ-
ously untreated native coronary artery lesions with length
28 mm and vessel diameter 2.5 to 3.75 mm were
enrolled. Major exclusion criteria (5) included recent MI,
left ventricular ejection fraction 30%, and complex lesions
including left main, ostial left anterior descending, or left
circumflex stenoses; totally occluded vessels; large bifurca-
tions; excessive calcification; tortuosity; angulation; or
thrombus.
Aspirin 300 mg was administered before catheteriza-
tion, with 80 mg daily continued indefinitely. A load-
ing dose of clopidogrel 300 mg was given, followed by
75 mg daily for 6 months (1 year strongly recom-
mended). Thienopyridine use after 1 year was left to
physician discretion. Clinical follow-up is ongoing
through 5 years. TLF components have been defined
elsewhere (5). Secondary endpoints included major ad-
verse cardiac events (cardiac death, MI, or ischemia-
ccording to Stent Randomizationacteristics According to Stent Randomization
atients
sions)
PES
(n  1,229 Patients
and 1,585 Lesions) p Value
.5 63.3 10.2 0.80
(67.7) 833/1,229 (67.8) 1.00
(77.4) 935/1,228 (76.1) 0.41
(76.1) 917/1,214 (75.5) 0.74
(32.0) 399/1,228 (32.5) 0.80
(8.5) 119/1,228 (9.7) 0.24
(21.9) 269/1,200 (22.4) 0.70
(21.1) 239/1,202 (19.9) 0.41
(27.7) 347/1,202 (28.9) 0.46
5 1.3 0.5 0.53
48 2.75 0.46 0.59
38 0.76 0.39 0.36
.6 72.0 12.8 0.44
7 14.5 6.6 0.24
77 1.46 0.78 0.35
44 1.14 0.41 0.01
39 3.01 0.38 0.70
9 20.9 8.9 0.001ics AChar
EES
458 P
42 Le
3 10
2,458
2,454
2,411
2,455
2,455
2,411
2,388
2,416
3 0.
5 0.
5 0.
3 12
8 6.
9 0.
7 0.
1 0.
4 8.
b
a
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June 28, 2011:19–25 2-Year Outcomes of the SPIRIT IV Trialdriven TLR), target vessel failure (cardiac death, MI, or
ischemia-driven target vessel revascularization), and def-
inite or probable stent thrombosis according to the
Academic Research Consortium criteria. All of these
endpoints and their components were pre-specified for
analysis at 2 years.
Statistical methods. Categorical variables were compared
y the Fisher exact test. Continuous variables are presented
s mean  SD and were compared by t test. Survival curves
were constructed for time-to-event variables using Kaplan-
Meier estimates and compared by log-rank test. A 2-sided
alpha of 0.05 was used for all superiority testing. Formal
Aspirin and Thienopyridine UsageTable 2 Aspirin and Thienopyridine Usage
E
(n 
Aspirin use
At discharge 2,434/2
At 1 yr 2,294/2
At 2 yrs 2,227/2
Thienopyridine use
At discharge 2,437/2
At 1 yr 2,228/2
At 2 yrs 1,671/2
Both aspirin and thienopyridine use
At discharge 2,422/2
At 1 yr 2,177/2
At 2 yrs 1,618/2
Neither aspirin nor thienopyridine use
At discharge 7/2
At 1 yr 30/2
At 2 yrs 49/2
Data are presented as n (%).
Abbreviations as in Table 1.
Adverse Events at 1- and 2-Year Follow-up According to Stent RandTable 3 Adverse Events at 1- and 2-Year Follow-up According t
1-Yr Outcomes
EES
(n  2,458)
PES
(n  1,229) HR (95%
Target lesion failure 4.0% (98) 6.7% (81) 0.62 (0.46
Major adverse cardiac events 4.1% (99) 6.8% (82) 0.61 (0.46
Target vessel failure 5.4% (131) 7.8% (95) 0.72 (0.55
All-cause death 1.0% (24) 1.2% (15) 0.83 (0.44
Cardiac 0.4% (10) 0.4% (5) 0.99 (0.34
Noncardiac 0.6% (14) 0.8% (10) 0.75 (0.33
All MI 1.9% (46) 3.0% (37) 0.62 (0.40
Q-wave 0.1% (3) 0.4% (5) 0.30 (0.07
Non–Q-wave 1.8% (43) 2.7% (33) 0.65 (0.41
Target vessel MI 1.8% (45) 2.9% (35) 0.64 (0.41
Cardiac death or target vessel MI 2.2% (54) 3.1% (38) 0.71 (0.47
Ischemia-driven TLR 2.4% (57) 4.6% (55) 0.54 (0.38
Ischemia-driven TVR 3.7% (89) 5.9% (71) 0.67 (0.49
Stent thrombosis 0.29% (7) 1.06% (13) 0.27 (0.11
Definite 0.25% (6) 0.82% (10) 0.30 (0.11
Probable 0.04% (1) 0.24% (3) 0.17 (0.02Data are presented as Kaplan-Meier estimates (no. of events), unless otherwise indicated.
CI  confidence intervals; HR  hazard ratio; MI  myocardial infarction; TLR  target lesion revascuinteraction testing was performed to determine whether
pre-specified subgroups influenced the relative risk of EES
versus PES for the primary TLF endpoint at 2 years.
Results
Patients, procedures, and antiplatelet medication adherence.
A total of 2,458 patients were assigned to EES, and 1,229
patients were assigned to PES. The EES and PES groups
were well matched (Table 1), with the exception of the
number of stents and total stent length/lesion, which were
increased in EES-treated patients because of fewer EES
stent lengths available. The majority of patients were
)
PES
(n  1,229) p Value
9.0) 1,220/1,229 (99.3) 0.58
6.8) 1,143/1,179 (96.9) 0.84
5.8) 1,111/1,154 (96.3) 0.58
9.1) 1,221/1,229 (99.3) 0.56
3.9) 1,111/1,179 (94.2) 0.76
1.8) 820/1,154 (71.1) 0.63
8.5) 1,218/1,229 (99.1) 0.16
1.9) 1,087/1,179 (92.2) 0.84
9.7) 795/1,154 (68.9) 0.64
.3) 4/1,227 (0.3) 0.76
.3) 12/1,179 (1.0) 0.62
.1) 18/1,154 (1.6) 0.30
ationnt Randomization
2-Yr Outcomes
p Value
EES
(n  2,458)
PES
(n  1,229) HR (95% CI) p Value
0.0009 6.9% (166) 9.9% (119) 0.70 (0.55–0.89) 0.003
0.0008 7.1% (171) 10.1% (121) 0.71 (0.56–0.89) 0.003
0.01 9.3% (224) 11.7% (140) 0.81 (0.65–0.99) 0.04
0.56 2.0% (49) 2.7% (32) 0.79 (0.51–1.23) 0.30
0.99 0.9% (21) 1.3% (15) 0.73 (0.38–1.40) 0.34
0.47 1.2% (28) 1.4% (17) 0.85 (0.47–1.54) 0.59
0.03 2.5% (60) 3.9% (47) 0.64 (0.44–0.94) 0.02
0.08 0.1% (3) 0.8% (9) 0.17 (0.04–0.61) 0.002
0.06 2.4% (57) 3.3% (40) 0.72 (0.48–1.08) 0.11
0.05 2.3% (55) 3.5% (42) 0.66 (0.44–0.99) 0.04
0.10 3.1% (75) 4.2% (51) 0.75 (0.53–1.07) 0.11
0.0007 4.5% (107) 6.9% (82) 0.66 (0.50–0.88) 0.004
0.009 6.8% (163) 8.9% (106) 0.78 (0.61–0.99) 0.04
0.003 0.42% (10) 1.23% (15) 0.36 (0.17–0.79) 0.008
0.01 0.33% (8) 0.99% (12) 0.37 (0.16–0.88) 0.02
0.08 0.08% (2) 0.24% (3) 0.33 (0.06–1.99) 0.20ES
2,458
,458 (9
,370 (9
,324 (9
,458 (9
,372 (9
,326 (7
,458 (9
,368 (9
,322 (6
,456 (0
,375 (1
,329 (2omizo Ste
CI)
–0.82)
–0.82)
–0.93)
–1.57)
–2.91)
–1.66)
–0.95)
–1.25)
–1.02)
–1.00)
–1.07)
–0.78)
–0.91)
–0.67)
–0.82)
–1.60)larization; TVR  target vessel revascularization; other abbreviations as in Table 1.
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2-Year Outcomes of the SPIRIT IV Trial June 28, 2011:19–25maintained on dual antiplatelet therapy throughout the
2-year follow-up period (Table 2).
Clinical outcomes. Follow-up at 2 years was available in
3,578 patents (97.0%), including 2,388 assigned to EES
and 1,190 assigned to PES. EES compared with PES
significantly reduced the 2-year rate of TLF (6.9% vs.
9.9%; hazard ratio: 0.70, 95% confidence interval: 0.55 to
0.89; p  0.003) (Table 3, Fig. 1). This absolute 3.0%
eduction in TLF (number needed to treat [NNT]: 33)
as comparable to the 2.7% absolute benefit with EES
resent at 1 year (NNT: 37). The 2-year reduction in
LF was driven by significant reductions in target vessel
I and ischemia-driven TLR, with nonsignificantly
ifferent rates of cardiac mortality. EES versus PES also
educed the 2-year rates of all-cause MI and Q-wave MI.
he 2-year rate of Academic Research Consortium
efinite or probable stent thrombosis was reduced by 64%
ith EES compared with PES (0.4% vs. 1.2%; hazard
Figure 1 Time-to-Event Curves Through 2-Year Follow-up
Time-to-event curves for target lesion failure (A), death or myocardial infarction (B
and definite or probable stent thrombosis (D). EES  everolimus-eluting stent(s);atio: 0.36, 95% confidence interval: 0.17 to 0.79; p 
.008). There were no significant differences between
ES and PES in clinical outcomes between 1 year and 2
ears (Table 4). The 2-year reduction in TLF with EES
ompared with PES was consistent across 11 pre-
pecified subgroups, with a borderline interaction present
n patients with versus without diabetes (Fig. 2).
iscussion
n the large-scale, prospective, randomized SPIRIT IV
rial, treatment of noncomplex lesions with EES rather
han PES resulted in significant reductions in MI, stent
hrombosis, and ischemia-driven TLR at 1 year, without
ignificant differences in all-cause or cardiac mortality. As
result, the 1-year primary endpoint of TLF was reduced
y 38% (absolute risk reduction 2.7%, NNT: 37). Be-
ween 1 year and 2 years, adverse events accrued equally
emia-driven target lesion revascularization (C),
hazard ratio; PES  paclitaxel-eluting stent(s).), isch
HR 
o
r
otherw
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June 28, 2011:19–25 2-Year Outcomes of the SPIRIT IV Trialwith both stent platforms such that at the end of the
second year of follow-up, EES compared with PES
resulted in a 30% relative and 3.0% absolute reduction in
TLF (NNT: 33). A similar pattern was noted for the
endpoints of MI, stent thrombosis, and ischemia-driven
TLR, with the benefits of EES compared with PES
realized at 1 year and maintained at the end of year 2.
The 64% 2-year reduction in stent thrombosis with EES
compared with PES is likely responsible for the reduction
in Q-wave MI noted with EES.
The observation that the reduction in TLR with EES was
durable between 1 year and 2 years with no late loss of clinical
efficacy in this large-scale clinical trial is reassuring given a prior
report from the SPIRIT II angiographic substudy of greater
incremental late loss between 6 months and 2 years with EES
compared with PES (4). Late clinical catch-up in TLR was not
bserved between the 2 stents in the SPIRIT II or III
andomized trials (4,6), although routine angiographic
follow-up in these studies may have biased the late results
against the greater late loss PES. In contrast to these earlier
trials, routine angiographic follow-up was not performed in
SPIRIT IV, thus establishing that the reduction in clinical
restenosis with EES compared with PES is stable over time, at
least through 2-year follow-up.
Although no loss of the safety or efficacy advantages of EES
versus PES was apparent between 1 year and 2 years of
follow-up, neither was any further incremental gain present.
These results differ from the COMPARE (Comparison of the
everolimus eluting XIENCE-V stent with the paclitaxel elut-
ing TAXUS LIBERTE stent in all-comers: a randomized
open label trial) (7), in which the advantages of EES versus
PES continued to increase over time. Whether these differ-
ences between the trials are due to enrollment of diverse patient
populations (mostly stable ischemic heart disease without
Adverse Events Between 1 Year and 2 Years (LTable 4 Adverse Events Between 1 Year an
EES
(n  2,458)
Target lesion failure 2.9% (68)
Major adverse cardiac events 3.1% (72)
Target vessel failure 4.1% (97)
All-cause death 1.0% (24)
Cardiac 0.5% (11)
Noncardiac 0.6% (13)
All MI 0.6% (14)
Q-wave 0.0% (0)
Non–Q-wave 0.6% (14)
Target vessel MI 0.4% (10)
Cardiac death or target vessel MI 0.9% (21)
Ischemia-driven TLR 2.1% (49)
Ischemia-driven TVR 3.2% (76)
Stent thrombosis 0.13% (3)
Definite 0.09% (2)
Probable 0.04% (1)
Data are presented as Kaplan-Meier estimates (no. of events), unless
Abbreviations as in Tables 1 and 3.complex lesions in SPIRIT IV vs. a more complex “all-comers”cohort in COMPARE), differences in prolonged dual anti-
platelet therapy administration (frequent at 2 years in SPIRIT
IV vs. infrequent at 2 years in COMPARE), or chance cannot
be answered with certainty.
The 2-year benefits of EES compared with those of PES
were consistent across 11 pre-specified subgroups, except
possibly patients with diabetes versus those without diabe-
tes, in whom a borderline interaction effect (p  0.08) was
present (as also suggested in SPIRIT III) (8). In patients
without diabetes, EES versus PES resulted in a significant
39% reduction in TLF at 2 years versus a nonsignificant 7%
reduction in patients with diabetes. A recent pooled patient-
level analysis from the SPIRIT II, SPIRIT III, SPIRIT IV, and
COMPARE trials found this interaction to be statistically
significant (9). Additional studies are warranted to under-
stand the mechanisms and influence of the glycemic state on
the differential vascular responses to rapamycin analogue-
eluting stents and PES (10,11).
The present study results do not apply to excluded patients,
such as those with acute thrombotic syndromes and complex
lesions. Whether the frequent use of dual antiplatelet therapy
at 2 years in the present trial was beneficial in either stent arm
is unknown and is the subject of ongoing randomized trials.
Subgroup analysis is inherently underpowered (12) and should
be considered exploratory and hypothesis generating. Finally,
5-year follow-up is required to fully characterize the late
differences between the 2 stent platforms. Nonetheless, the
current results were consistent with the 3-year pooled results
from the SPIRIT II and III trials (13).
Conclusions
In the large-scale, prospective, multicenter, randomized
ark Analysis)ears (Landmark Analysis)
PES
(n  1,229) HR (95% CI) p Value
3.9% (46) 0.80 (0.55–1.15) 0.23
4.1% (48) 0.81 (0.56–1.15) 0.24
4.9% (57) 0.90 (0.65–1.24) 0.51
1.4% (17) 0.76 (0.41–1.40) 0.38
0.9% (10) 0.60 (0.26–1.38) 0.22
0.6% (7) 0.99 (0.40–2.46) 0.99
0.9% (11) 0.68 (0.31–1.48) 0.32
0.3% (4) — 0.005
0.6% (7) 1.07 (0.43–2.62) 0.89
0.7% (8) 0.68 (0.27–1.70) 0.41
1.4% (16) 0.71 (0.38–1.35) 0.30
2.7% (32) 0.84 (0.54–1.29) 0.42
3.7% (43) 0.94 (0.65–1.35) 0.72
0.17% (2) 0.99 (0.18–5.41) 0.99
0.17% (2) 0.74 (0.12–4.45) 0.74
0.00% (0) — 0.48
ise indicated.andmd 2 YSPIRIT IV trial, the benefits of EES compared with those of
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2-Year Outcomes of the SPIRIT IV Trial June 28, 2011:19–25PES present at 1 year in reducing TLF, MI, stent thrombosis,
and ischemia-driven TLR were sustained at 2 years.
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